GILD Gilead Sciences Net earnings per share growth forecast for next year

gilead.com (GILD) - corporate logo

The EPS growth guidance for Gilead Sciences, Inc. (GILD) for the coming year reflects market expectations, with the value stabilizing at 1175.40. Gilead Sciences, Inc. (GILD) attracts top researchers by providing generous laboratory funding. High technological potential enables the development of cancer cell therapy and the fight against HIV. Dominance in the antiviral sector provides the capital necessary to acquire promising biotech startups.

GILD: Gilead Net earnings per one share growth forecast for next year 07/04/2022 - 11/18/2026

Comprehensive metric breakdowns and analytics for Gilead Sciences (GILD)

Fundamental company analysis:Gilead Corp, GILD
Core merchandise of gilead.com

The fundamental value of Gilead Sciences, Inc. (GILD) is determined by its ability to generate stable cash flow from life-saving drugs. This metric measures the expected profit dynamics for the coming year, signaling a revision of analyst estimates under the influence of cost inflation. By analyzing the trends in the company's EPS forecasts for next year, an investor can identify institutional capital exit points. A decline in this metric offsets the effect of inertial demand, turning the asset into a vulnerable instrument.

Main competitors

Expected earnings per share growth for next year CDTX|Earnings growth forecast for next year novavax.com|Net earnings per share growth forecast for next year CureVac NV (CVAC)|Consensus forecast of earnings per share growth for next year Valneva Pharma|Earnings growth forecast for next year VIR (Vir Corp)|Consensus forecast of earnings per share growth for next year SIGA Corp (SIGA)|Emergent BioSolutions Inc - Earnings growth forecast for next year|Atea Pharmaceuticals - Projected earnings per share increase next year|IVVD (Invivyd Inc) - Expected earnings per share growth for next year|Enanta Pharmaceuticals Inc. (ENTA) - Earnings growth forecast for next year|INO (Inovio Pharma) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year HLVX|Net earnings per share growth forecast for next year Kalaris Therapeutics Inc (KLRS)|Consensus forecast of earnings per share growth for next year Dyadic International, Inc.|Earnings growth forecast for next year NNVC (nanoviricides.com)|Talphera Inc (TLPH) - Expected net earnings per share growth next year|COCP: Expected earnings per share growth for next year|Net earnings per share change forecast for next year TRAW|DWTX (Virios Therapeutics) - Expected earnings per share growth for next year|Projected earnings per share growth rate for next year QLGN|ALVR (AlloVir) - Earnings growth forecast for next year|vbivaccines.com (VBIV) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year VIRI|Expected earnings per share growth for next year Vaxart Corp VXRT